Please ensure Javascript is enabled for purposes of website accessibility

Why TransEnterix Stock Surged Today and Then Gave Up All its Gains

By Joe Tenebruso - Updated Jan 20, 2021 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The robotic surgery specialist is helping to enhance the capabilities of surgeons, but its shares may have come too far, too fast.

What happened

Shares of TransEnterix (ASXC 9.03%) soared as much as 27.2% on Wednesday before surrendering their gains and finishing the trading day down less than 1%.

So what

TransEnterix received approval in Europe on Tuesday for its Intelligent Surgical Unit (ISU), which adds machine-vision functions to the Senhance Surgical System. Senhance digital laparoscopic surgery programs in Europe will now have access to this innovative augmented-intelligence technology. 

"We have already successfully implemented augmented intelligence in the U.S. with the Senhance System after receiving [Food and Drug Administration] clearance last year," CEO Anthony Fernando said in a press release. "We are pleased to expand this important capability to our broader global user base."

By providing an enhanced ability to recognize certain objects and track locations, the ISU's machine-vision capabilities help surgeons better visualize the surgical area, while also giving them more precise control over camera movements. Additionally, surgical teams can more easily work together in the operating room by sharing the surgeon's console view in real time.

A person is pointing to a digital stock chart that rises sharply and then falls.

TransEnterix's stock price rose sharply before reversing course on Wednesday. Image source: Getty Images.

Now what

The Senhance Surgical System can be used for multiple types of minimally-invasive laparoscopic surgeries in the chest, abdomen, and pelvis. Surgeons perform more than 6 million procedures in these areas in the U.S. and Europe every year. It's a potentially massive market for TransEnterix, and investors are understandably intrigued by the possibilities.

But at its highs on Wednesday, the stock price had more than doubled following the announcement of its European approval on Tuesday morning. Many investors likely decided to lock in some gains and sell their shares at that point, which could be why TransEnterix's stock price ended the trading day essentially flat on Wednesday.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
ASXC
$0.42 (9.03%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.